New York, New York--(Newsfile Corp. - December 7, 2024) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of ASP Isotopes Inc. (NASDAQ: ASPI) between October 30, 2024 and November 26, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 3, 2025.
If you purchased ASP Isotopes securities during the Class Period you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
"We encourage investors to select qualified counsel with a track record of success in leadership roles," states Rosen Law Firm.
The Rosen Law Firm represents investors throughout the globe and concentrates its practice in securities class actions and shareholder derivative litigation. The firm achieved the largest ever securities class action settlement against a Chinese Company at the time. It was ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017 and has been ranked in the top four each year since 2013. In 2019 alone the firm secured over $438 million for investors.
Details of the Case
According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:
- ASP Isotopes overstated the potential effectiveness of its enrichment technology;
- ASP Isotopes overstated the development potential of its high assay low-enriched uranium facility;
- ASP Isotopes overstated the Company's nuclear fuels operating segment results; and
- As a result of these issues, defendants' positive statements about ASP Isotope's business were materially misleading or lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice or remain an absent class member without taking any action at this point.
"An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff," says Rosen Law Firm.